Abstract
We have investigated the feasibility of individual dose-monitoring of doxorubicin in lymphoma patients. The purpose was to overcome the large variability of the early-phase kinetic parameters of the drug. We have used a test-dose and calculated for 32 patients a therapeutic dose which could allow us to obtain a predetermined early drug exposure. Such a predetermined drug exposure was obtained in 24 patients of the study. Important variations of the early clearance occurred in 8 patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
O’Bryan R M, Baker L H, Gottlieb J E, Rivkin S E, Balcerzak S P, Grumet G N, Salmon S E, Moon T E, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia.Cancer 39, 1940 (1977).
Robert J, Iliadis A, Hoerni B, Cano J P, Durand M, Lagarde C: Pharmacokinetics of doxorubicin in patients with breast cancer. Correlation between pharmacokinetic parameters and clinical short-term response.Eur J Cancer Clin Oncol 8, 739 (1982).
Benjamin R S, Riggs C E, Jr, Bachur N R: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.Cancer Res 37, 1416 (1977).
Piazza E, Donelli M G, Broggini M, Sessa C, Natale N, Ottolenghi L, Marsoni S, Libretti A, Mangioni C, Marasco L: Early-phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single or multiple-drug therapy.Cancer Treat Rep 64, 845 (1980).
Monjanel S, Rigault J P, Cano J P, Carcassonne Y, Favre R: High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.Cancer Chemother Pharmac 3, 189 (1979).
Robert J, Vrignaud P, Iliadis A, Eghbali H, Hoerni B: Etude pharmacocinétique de la doxorubicine dans le traitement des lymphomes malins non Hodgkiniens.Nouv Rev Fr Hematol 25, 91 (1983).
Robert J, Hoerni B, Vrignaud P, Lagarde C: Earlyphase-pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.Cancer Chemother Pharmac 10, 115 (1983).
Rappaport H, Berard C W, Butler J J, Dorfman R F, Lukes R J, Thomas L B: Report of the Committee on histopathological criteria contributing to staging of Hodgkin’s disease.Cancer Res 31, 1864 (1971).
Lennert K (ed).Histopathologie der non-Hodgkin Lymphome nach der Kiel-Klassifikation. Berlin, Springer (1981).
Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M: Report of the Committee on Hodgkin’s disease staging classification.Cancer Res 31, 1860 (1971).
Chauvergne J, Durand M, Hoerni B, Hoerni-Simon G, Brunet R, Lagarde C: Induction chemotherapy of non-Hodgkin’s malignant lymphomas. Preliminary results of a controlled trial.Eur J Cancer 13, 399 (1977).
Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi G: Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastin and imidazole carboxamide versus M. O. P. P.Cancer 36, 252 (1975).
Robert J: Extraction of anthracyclines from biological fluids for HPLC evaluation.J Liquid Chromatogr 3, 1561 (1980).
Israel M, Peng W J, Wilkinson P M, Garnick M B: Liquid chromatographic analysis of adriamycin and metabolites in biological fluids.J Liquid Chromatogr 1, 795 (1978).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robert, J., Vrignaud, P., Eghbali, H. et al. Tentative dose-monitoring of doxorubicin in lymphoma patients. Med. Oncol. & Tumor Pharmacother. 2, 255–259 (1985). https://doi.org/10.1007/BF02934911
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02934911